J. Goldman & Co’s Amicus Therapeutics FOLD Stock Holding History

J. Goldman & Co’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-387,654	Closed	-$4.3M	–	416
2023 Q1	$4.3M	Buy	387,654 +162,743	+72%	+$2.01M	0.17%	156
2022 Q4	$2.75M	Buy	+224,911	New	+$2.53M	0.13%	155
2022 Q1	–	Sell	-170,946	Closed	-$1.6M	–	392
2021 Q4	$1.97M	Buy	170,946 +129,511	+313%	+$1.44M	0.11%	204
2021 Q3	$396K	Buy	+41,435	New	+$424K	0.02%	293
2019 Q4	–	Sell	-161,946	Closed	-$1.48M	–	293
2019 Q3	$1.3M	Buy	+161,946	New	+$1.76M	0.1%	177
2018 Q2	–	Sell	-81,618	Closed	-$1.23M	–	384
2018 Q1	$1.23M	Sell	81,618 -142,504	-64%	-$2.17M	0.05%	253
2017 Q4	$3.23M	Buy	224,122 +20,622	+10%	+$283K	0.17%	150
2017 Q3	$3.07M	Buy	+203,500	New	+$2.69M	0.15%	164
2016 Q4	–	Sell	-88,800	Closed	-$657K	–	323
2016 Q3	$657K	Buy	+88,800	New	+$600K	0.04%	261
2015 Q1	–	Sell	-400,000	Closed	-$3.53M	–	278
2014 Q4	$3.33M	Buy	+400,000	New	+$2.75M	0.39%	84

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

J. Goldman & Co's FOLD Position: Q2 2023 in Review

J. Goldman & Co sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 387,654 shares — an estimated $4.3M sold.

J. Goldman & Co first reported a position in FOLD in Q4 2014 and held it in 10 quarters. The position peaked at $4.3M in Q1 2023. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

J. Goldman & Co reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
J. Goldman & Co sold 387,654 Amicus Therapeutics shares in Q2 2023, an estimated $4.3M.
J. Goldman & Co first reported a position in Amicus Therapeutics in Q4 2014 and held it in 10 quarters.
J. Goldman & Co's Amicus Therapeutics position peaked at $4.3M in Q1 2023.
216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.